These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 19503767

  • 1. A case of subretinal neovascularization treated with intravitreal ranibizumab in a patient with idiopathic juxtafoveal retinal telangiectasis.
    Karagiannis D, Georgalas I, Ladas I, Eustratios P, Mitropoulos P.
    Clin Interv Aging; 2009; 4():63-5. PubMed ID: 19503767
    [Abstract] [Full Text] [Related]

  • 2. Intravitreal ranibizumab and bevacizumab for bilateral subretinal neovascularization secondary to idiopathic juxtafoveal telangiectasia type 2A.
    Mavrakanas N, Mendrinos E, Pournaras CJ, Salzmann J.
    Acta Ophthalmol; 2009 Nov; 87(8):930-2. PubMed ID: 19706015
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia.
    Mandal S, Venkatesh P, Abbas Z, Vohra R, Garg S.
    Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1825-9. PubMed ID: 17345090
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Photodynamic therapy of a subretinal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis.
    Potter MJ, Szabo SM, Chan EY, Morris AH.
    Am J Ophthalmol; 2002 Jan; 133(1):149-51. PubMed ID: 11755857
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Ranibizumab in retinal angiomatous proliferation (RAP): influence of RAP stage on visual outcome.
    Reche-Frutos J, Calvo-Gonzalez C, Pérez-Trigo S, Fernandez-Perez C, Donate-Lopez J, Garcia-Feijoo J.
    Eur J Ophthalmol; 2011 Jan; 21(6):783-8. PubMed ID: 21484755
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization.
    Konstantinidis L, Mantel I, Pournaras JA, Zografos L, Ambresin A.
    Graefes Arch Clin Exp Ophthalmol; 2009 Mar; 247(3):311-8. PubMed ID: 19043731
    [Abstract] [Full Text] [Related]

  • 18. Microperimetric retinal changes in myopic choroidal neovascularization treated with intravitreal ranibizumab.
    Varano M, Tedeschi M, Oddone F, Perillo L, Coppè AM, Parravano M.
    Retina; 2010 Mar; 30(3):413-7. PubMed ID: 20010453
    [Abstract] [Full Text] [Related]

  • 19. Predictive Value of Retinal Morphology for Visual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD.
    Waldstein SM, Wright J, Warburton J, Margaron P, Simader C, Schmidt-Erfurth U.
    Ophthalmology; 2016 Jan; 123(1):60-9. PubMed ID: 26481821
    [Abstract] [Full Text] [Related]

  • 20. Juxtafoveal choroidal neovascularization secondary to persistent placoid maculopathy treated with intravitreal bevacizumab.
    Parodi MB, Iacono P, Bandello F.
    Ocul Immunol Inflamm; 2010 Oct; 18(5):399-401. PubMed ID: 20666681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.